Addendum
Atezolizumab (hepatocellular carcinoma) - Addendum to Commission A20-97
Report documents
-
Addendum
Atezolizumab (hepatocellular carcinoma) - Addendum to Commission A20-97
Dossier assessment
Indication:
Adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy
Result of dossier assessment:
unchanged after addendum:
Patients with Child-Pugh A or no liver cirrhosis
- with viral aetiology of HCC: indication of major added benefit,
- with non-viral aetiology of HCC: hint of considerable added benefit.
Patients with Child-Pugh B: added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2021-05-20: A G-BA decision was published
Project details
- Project no.
- A21-45
- Commission
- Commission awarded on 07.04.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed